Clinical Guideline InSights
The 2026 Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events Scientific Statement and the 2026 Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease Scientific Statement * Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events/Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease * American College of Cardiology * June 30, 2026 * Guideline Summary: https://www.guidelinecentral.com/guideline/5230408/ [https://www.guidelinecentral.com/guideline/5230408/] / https://www.guidelinecentral.com/guideline/5230407/ [https://www.guidelinecentral.com/guideline/5230407/] * Full-Text: https://www.jacc.org/doi/10.1016/j.jacc.2026.05.033 [https://www.jacc.org/doi/10.1016/j.jacc.2026.05.033] / https://www.jacc.org/doi/10.1016/j.jacc.2026.05.037#tbl2 [https://www.jacc.org/doi/10.1016/j.jacc.2026.05.037#tbl2]
57 Episoder
Kommentarer
0Vær den første til å kommentere
Registrer deg nå og bli medlem av Clinical Guideline InSights sitt community!